(3R)-3-methyl-4-[5-methyl-4-(1-methylindol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine
C26H26N6O — CID 138610662
Data last refreshed: (MolForge compound catalog, from PubChem)
About (3R)-3-methyl-4-[5-methyl-4-(1-methylindol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine
(3R)-3-methyl-4-[5-methyl-4-(1-methylindol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine (PubChem CID 138610662) has the molecular formula C26H26N6O and a molecular weight of 438.54 g/mol. Its IUPAC name is (3R)-3-methyl-4-[5-methyl-4-(1-methylindol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine.
Molecular Properties
| Compound Name | (3R)-3-methyl-4-[5-methyl-4-(1-methylindol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine |
|---|---|
| PubChem CID | 138610662 |
| Molecular Formula | C26H26N6O |
| Molecular Weight | 438.54 g/mol |
| Exact Mass | 438.22 |
| IUPAC Name | (3R)-3-methyl-4-[5-methyl-4-(1-methylindol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine |
| SMILES | Cc1cnc(-c2ccn[nH]2)c2nc(N3CCOC[C@H]3C)cc(-c3ccc4c(ccn4C)c3)c12 |
| InChI | InChI=1S/C26H26N6O/c1-16-14-27-25(21-6-8-28-30-21)26-24(16)20(13-23(29-26)32-10-11-33-15-17(32)2)18-4-5-22-19(12-18)7-9-31(22)3/h4-9,12-14,17H,10-11,15H2,1-3H3,(H,28,30)/t17-/m1/s1 |
| InChIKey | HMAFHVDVWJJOGN-QGZVFWFLSA-N |
| XLogP | 4.71 |
| TPSA | 71.86 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 438.54 |
| LogP ≤ 5 | 4.71 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 138610662 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.